Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: AstraZeneca
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
An International, Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled, Active-controlled Study of the Efficacy and Safety of Sustained-release Quetiapine Fumarate (Seroquel SR™ ) in the Treatment of Generalized Anxiety Disorder (SILVER Study)
The primary objective of this study is to evaluate the efficacy of (SEROQUEL SR™ ) quetiapine fumarate sustained-release (SR) compared to placebo in the treatment of anxiety symptoms in patients with ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A Phase I/II randomised, double-blind, multi-centre study to assess the efficacy of AZD2281 when given in combination with paclitaxel in the 1st or 2nd line treatment of patients with metastatic Triple Negative Breast Cancer
The primary objective of the Phase I part of this study is: · To establish the appropriate doses of paclitaxel and AZD2281 in combination, based on safety and tolerability (for use in the randomised P...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A 12-Week, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multinational, Phase IIb Study to Evaluate the Efficacy and Safety of 60 mg AZD9668 Administered Orally Twice Daily to Subjects with Chronic Obstructive Pulmonary Disease (COPD) on Treatment with budesonide/formoterol
To evaluate the efficacy of AZD9668 compared with placebo in symptomatic COPD subjects by assessing effect on lung function and symptoms of COPD.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A Short-term 12-Week, Multi-centre, Randomized, Parallel-group, Double-blind, Placebo-controlled Study to Evaluate the Treatment Effect of Saxagliptin compared with Placebo in Adult Patients with Type 2 Diabetes and Renal Impairment (Moderate, Severe, and End-Stage) with an additional 40-week, Randomized, Parallel-group, Double-blind, Placebo-controlled Long-term Observational Period
Short-term: To evaluate the efficacy of saxagliptin 2.5 mg in adult patients with type 2 diabetes and renal impairment (moderate, severe and end-stage) compared with placebo by assessment of the absol...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A randomised, double-blind, phase III efficacy and safety study of cediranib (RECENTIN™ ) when added to cisplatin plus a fluoropyrimidine, compared with cisplatin plus a fluoropyrimidine alone, in patients with previously untreated, locally advanced or metastatic, unresectable Gastric Cancer (GC)
To determine the efficacy of cediranib when added to cisplatin plus a fluoropyrimidine compared to cisplatin plus a fluoropyrimidine alone by assessment of overall survival (OS).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years and 130 years
AstraZeneca
Update Il y a 4 ans
Étude D5160C00035 : étude de phase 1 visant à évaluer la pharmacocinétique, la sécurité d’emploi et la tolérance de l’osimertinib chez des patients ayant des tumeurs solides avancées et avec une fonction rénale normale ou une insuffisance rénale sévère. [essai clos aux inclusions]
Les tumeurs solides peuvent se développer dans n’importe quel tissu : peau, muqueuses, os, organes, etc. Ce sont les plus fréquents puisque, à eux seuls, ils représentent 90% des cancers humains. L’o...
Country
France
organs
Tumeurs solides
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A Phase III Study of MEDI4736 versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Estudio de fase III de MEDI4736 frente al tratamiento estándar en pacientes con carcinoma pulmonar no microcítico localmente avanzado
To assess the efficacy of MEDI4736 treatment compared with Standard of Care in terms of Overall survival (OS) and Progression free survival (PFS). Evaluar la eficacia del tratamiento con MEDI473...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years and 130 years
AstraZeneca
Update Il y a 4 ans
Étude NIAGARA : étude de phase 3, randomisée, en ouvert, visant à déterminer l'efficacité et la tolérance d'un traitement associant le durvalumab et une chimiothérapie par gemcitabine et cisplatine comme traitement néoadjuvant, suivi par du durvalumab seul comme traitement adjuvant, chez des patients ayant un cancer de la vessie sans envahissement musculaire.
A phase III, randomized, open-label, multi-center, global study to determine the efficacy and safety of durvalumab in combination with gemcitabine+cisplatin for neoadjuvant treatment followed by durva...
Country
France
organs
Vessie
Specialty
Immunothérapie - Vaccinothérapie
,
Chimiothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
AstraZeneca GmbH
Update Il y a 4 ans
RACE : Rapid Dose Escalation of Quetiapine versus Conventional Escalation in the Treatment of Patients with Acute Schizophrenia – a Multicentre, Double-blind, Parallel group, Randomized Study
The primary objective for the study is to evaluate the safety and tolerability of IR (Immediate-Release) quetiapine in a rapid escalation scheme (300 mg on day 1, 600 mg on day 2 and 800 mg on day 3) ...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
AstraZeneca AB
Update Il y a 4 ans
A Randomized, Open-label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg with Fulvestrant (FASLODEX™) 250 mg when given as Neoadjuvant Treatment in Postmenopausal Women with Estrogen Receptor Positive Breast Cancer (T2, 3, 4b, N0-3, M0)
To compare the effects of fulvestrant 500 mg and fulvestrant 250 mg on the proliferation marker Ki67 at 4 weeks
Country
None
organs
None
Specialty
None
Closed trial
More information
Previous
4
5
6
7
8
9
10
11
12
13
Next